New Two-Pronged attack on returning ovarian cancer begins testing
NCT ID NCT07454018
Summary
This study is testing a new combination treatment for women whose ovarian cancer has returned but still responds to platinum-based chemotherapy. It first combines a new two-in-one immunotherapy drug with standard chemotherapy, then switches to a maintenance pill called olaparib. The goal is to see if this two-part strategy can better control the cancer and delay its progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.